arrow
C

Christa M. Cobbaert

Leiden University
H指数:44
被引数:7,993

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical performance of the next generation Elecsys Troponin T high-sensitivity Gen 6 assay in acute coronary syndrome (PERFORM-TSIX): study design
2026-01-190
OAAI
Establishing Reference Values in Healthy Participants for the Cardiac Troponin T High-Sensitivity Gen 6 Assay: REF-TSIX Global Reference Study

建立健康受试者中用于心肌肌钙蛋白T高灵敏度Gen 6检测的参考值:REF-TSIX全球参考研究

2026-01-015
PRE
Protein N-Glycosylation Traits Combined With CA19-9 Accurately Distinguish Pancreatic Cancer Cases From Healthy Controls and Benign Pancreatic Diseases

蛋白N-糖基化特征与CA19-9结合,能准确区分胰腺癌病例与正常对照组和良性胰腺疾病。

2025-10-010
PRE
Corrigendum to “Quantitative protein mass spectrometry for multiplex measurement of coagulation and fibrinolytic proteins towards clinical application: What, why and how?”, [Thromb. Res. 241 (2024) 109090]

勘误:“Quantitative protein mass spectrometry for multiplex measurement of coagulation and fibrinolytic proteins towards clinical application: What, why and how?”, [Thromb. Res. 241 (2024) 109090]

2025-08-010
OA
Design and rationale of the HARTc 2.0 trial: a multicentre randomized controlled study on the impact of point-of-care hs-cTnI testing in prehospital ACS triage on diagnosis and cost-effectiveness

HARTc 2.0试验的设计与原理:一项关于床旁hs-cTnI检测对院前ACS分诊的诊断及成本效益影响的多中心随机对照研究

2025-07-160
PREAI
Is this test fit-for-purpose? Principles and a checklist for evaluating the clinical performance of a test in the new era of in vitro diagnostic (IVD) regulation

这个测试适合目的吗?在体外诊断 (IVD) 法规的新时代中评估测试临床性能的原则和清单

2025-02-060
OA
Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes With Alirocumab: Post Hoc Analyses of the ODYSSEY OUTCOMES Randomized Trial

与脂蛋白(a)、低密度脂蛋白胆固醇及其在Alirocumab作用下变化相关的糖尿病发生风险:ODYSSEY OUTCOMES随机试验的事后分析

2025-02-060
PRE